What question did this study set out to answer?

This research compares the efficacy and safety of two treatment combinations for unresectable hepatocellular carcinoma.

March 5, 2026Open Access

Comparison of the efficacy of transarterial chemoembolization combined with radiofrequency ablation or sintilimab and bevacizumab for unresectable hepatocellular carcinoma

TLTingting LiBeijing Shijitan Hospital HZHongyi ZhaoBeijing Shijitan Hospital CDChengbin DongBeijing Shijitan Hospital

Key Points

This research compares the efficacy and safety of two treatment combinations for unresectable hepatocellular carcinoma.
Retrospective cohort study
Included 207 patients with unresectable HCC
Compared TACE combined with RFA vs. TACE with sintilimab and bevacizumab
Analyzed baseline characteristics, tumor response, and survival outcomes
Statistical analyses included t-tests, χ² tests, and multivariable Cox regression
Dual-drug group achieved a higher objective response rate (38.60% vs. 24.73%)
Median overall survival for dual-drug therapy was longer (27.24 months vs. 24.17 months)
Higher progression-free survival in dual-drug group (10.42 months vs. 8.13 months)
Dual-drug therapy associated with lower risk of death (HR = 0.520)
Increased adverse events like hypertension and hepatic dysfunction in dual-drug group

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality. For patients with unresectable HCC, transarterial chemoembolization (TACE) combined with either radiofrequency ablation (RFA) or systemic therapy (e.g., sintilimab and bevacizumab) are emerging strategies. This study aims to compare the efficacy and safety of TACE-RFA versus TACE combined with sintilimab and bevacizumab in unresectable HCC. This retrospective cohort study included 207 patients with unresectable HCC treated from January 2021 to June 2022: 93 received TACE combined RFA and 114 received TACE combined sintilimab and bevacizumab. Baseline characteristics, laboratory parameters, tumor response, adverse events, and survival outcomes (overall survival OS and progression-free survival PFS) were analyzed. Statistical analyses employed t-tests, χ² tests, Kaplan-Meier/log-rank tests, and multivariable Cox regression to identify independent prognostic factors. Baseline characteristics were comparable. The TACE+dual-drug group achieved a higher objective response rate (ORR: 38.60% vs. 24.73%, P = 0.034) and superior survival outcomes, with longer median OS (27.24 vs. 24.17 months, P < 0.001) and PFS (10.42 vs. 8.13 months, P < 0.001). Multivariable Cox regression identified treatment group and BCLC stage as independent predictors of OS. Compared to TACE + RFA, TACE+dual-drug therapy was associated with a significantly lower risk of death (HR = 0.520, 95% CI: 0.370–0.731, P < 0.001), while BCLC stage C increased the risk of death (HR = 2.106, 95% CI: 1.412–3.146, P < 0.001). Regarding safety, the dual-drug group exhibited more pronounced hematological suppression, coagulopathy, and hepatic dysfunction (P < 0.05). Adverse events (hypertension, hand-foot syndrome, rash) were significantly more common in the TACE+dual-drug group (P < 0.01). TACE combined with sintilimab and bevacizumab improves survival and tumor response over TACE-RFA but with increased systemic toxicity. Patient selection should balance efficacy and tolerability.

KI fragen

Bookmark

View Full Paper

Cite This Study

Li et al. (Tue,) studied this question.

synapsesocial.com/papers/69a91dedd6127c7a504c13c1 https://doi.org/https://doi.org/10.1186/s12876-026-04672-1

KI fragen

Bookmark

View Full Paper